Free Access
| Issue |
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1014 - 1016 | |
| Section | Les anticorps dans les maladies autres qu’oncologiques | |
| DOI | https://doi.org/10.1051/medsci/2019224 | |
| Published online | 06 January 2020 | |
- Investigators EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 ; 330: 956–961. [Google Scholar]
- Smith TW, Haber E, Yeatman L, et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976 ; 294: 797–800. [Google Scholar]
- Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008 ; 136: 884–893. [CrossRef] [PubMed] [Google Scholar]
- Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001 ; 104: 2778–2783. [CrossRef] [PubMed] [Google Scholar]
- Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001 ; 88: 482–487. [CrossRef] [PubMed] [Google Scholar]
- Stähli BE, Gebhard C, Duchatelle V, et al. Effects of the P-selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: Insights from the SELECT-ACS trial. J Am Heart Assoc 2016; 5. [Google Scholar]
- Carroll MB, Haller C, Smith C. Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol Int 2018 ; 38: 59–66. [Google Scholar]
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 2017 ; 377: 1119–1131. [Google Scholar]
- Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017 ; 390: 1833–1842. [CrossRef] [PubMed] [Google Scholar]
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 ; 34: 1546. [Google Scholar]
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 ; 376: 17: 1322. [Google Scholar]
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018 ; 379: 2097–2107. [Google Scholar]
- Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med 2017 ; 376: 1527–1539. [Google Scholar]
- Stoekenbroek RM, Kallend D, Wijngaard PL, et al. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol 2018 ; 14: 433–442. [CrossRef] [PubMed] [Google Scholar]
- Daifotis AG, Koenig S, Chatenoud L, et al. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013 ; 149: 268–278. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.